Consolidated Financial Statements and Independent Auditors' Reports as Required by Title 2 *U.S. Code of Federal Regulations* Part 200*, Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards and Government Auditing Standards* and Related Information

Cold Spring Harbor Laboratory

December 31, 2024 and 2023

Contents

	Page
Report of Independent Certified Public Accountants	3
Consolidated Financial Statements	
Consolidated balance sheets	6
Consolidated statements of activities	7
Consolidated statements of cash flows	9
Notes to consolidated financial statements	10
Uniform Guidance Supplementary Information	
Schedule of expenditures of federal awards	33
Notes to schedule of expenditures of federal awards	37
Report of Independent Certified Public Accountants on Internal Control Over Financial Reporting and on Compliance and Other Matters Required by *Government Auditing Standards*	38
Report of Independent Certified Public Accountants on Compliance for Each Major Federal Program and on Internal Control Over Compliance Required by the Uniform Guidance	40
Schedule of findings and questioned costs	
Section I - summary of auditor's results	43
Section II - financial statement findings	44
Section III - findings and questioned costs for federal awards	44

GRANT THORNTON LLP
445 Broadhollow Road, Suite 300
Melville, NY 11747

D +1 631 249 6001
F +1 631 249 6144

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS

Board of Trustees
Cold Spring Harbor Laboratory

Report on the audit of the financial statements

Opinion

We have audited the consolidated financial statements of Cold Spring Harbor Laboratory (the "Laboratory"), which comprise the consolidated balance sheets as of December 31, 2024 and 2023, and the related consolidated statements of activities and cash flows for the years then ended, and the related notes to the consolidated financial statements.

In our opinion, the accompanying consolidated financial statements present fairly, in all material respects, the consolidated financial position of the Laboratory as of December 31, 2024 and 2023, and the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for opinion

We conducted our audits of the consolidated financial statements in accordance with auditing standards generally accepted in the United States of America (US GAAS) and the standards applicable to financial audits contained in *Government Auditing Standards*, issued by the Comptroller General of the United States (*Government Auditing Standards*). Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Statements section of our report. We are required to be independent of the Laboratory and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audits. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of management for the financial statements

Management is responsible for the preparation and fair presentation of the consolidated financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of consolidated financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the consolidated financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Laboratory's ability to continue as a going concern for one year after the date the financial statements are issued.

Grant Thornton LLP is a U.S. member firm of Grant Thornton International Ltd (GTIL). GTIL and each of its member firms are separate legal entities and are not a worldwide partnership.

Auditor's responsibilities for the audit of the financial statements
Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS and *Government Auditing Standards* will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the consolidated financial statements.

In performing an audit in accordance with US GAAS and *Government Auditing Standards*, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Laboratory's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the consolidated financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Laboratory's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplementary information
Our audits were conducted for the purpose of forming an opinion on the consolidated financial statements as a whole. The schedule of expenditures of federal awards, as required by Title 2 *U.S. Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards*, is presented for purposes of additional analysis and is not a required part of the consolidated financial statements. Such supplementary information is the responsibility of management and was derived from and relates

directly to the underlying accounting and other records used to prepare the consolidated financial statements. The information has been subjected to the auditing procedures applied in the audits of the consolidated financial statements and certain additional procedures. These additional procedures included comparing and reconciling such information directly to the underlying accounting and other records used to prepare the consolidated financial statements or to the consolidated financial statements themselves, and other additional procedures in accordance with US GAAS. In our opinion, the accompanying supplementary information is fairly stated, in all material respects, in relation to the consolidated financial statements as a whole.

Other reporting required by *Government Auditing Standards*

In accordance with *Government Auditing Standards*, we have also issued our report dated May 1, 2025 on our consideration of the Laboratory's internal control over financial reporting and on our tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements and other matters. The purpose of that report is solely to describe the scope of our testing of internal control over financial reporting and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Laboratory's internal control over financial reporting or on compliance. That report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Laboratory's internal control over financial reporting and compliance.

Grant Thornton LLP

Melville, New York
May 1, 2025

Cold Spring Harbor Laboratory

CONSOLIDATED BALANCE SHEETS

December 31,

ASSETS	**2024**	**2023**
Cash and cash equivalents:		
Board designated for capital expansion	$ 24,961,115	$ 19,547,834
Available for working capital	18,404,777	17,364,567
Grants receivable	11,265,142	9,278,903
Contributions receivable, net	105,578,026	139,232,929
Investments in certificates of deposit:		
Board designated for capital expansion	21,027,000	58,330,665
Available for working capital	15,149,898	32,232,315
Investments	849,540,158	766,313,926
Investment in employee residences	7,280,837	6,809,903
Restricted use assets	620,041	545,643
Deposits with bond trustee	66,368,748	-
Other assets	8,987,083	9,106,751
Right-of-use assets - operating	4,510,199	318,586
Land, buildings, and equipment, net	380,535,376	318,368,175
Total assets	$1,514,228,400	$1,377,450,197
LIABILITIES AND NET ASSETS		
Liabilities		
Accounts payable and accrued expenses	$ 14,825,475	$ 10,944,153
Deferred revenue	11,826,255	22,376,812
Operating lease liability	4,624,565	341,366
Fair value of interest rate swap	7,355,377	12,189,072
Bonds payable	181,076,115	96,139,041
Total liabilities	219,707,787	141,990,444
Commitments and contingencies		
Net assets		
Without donor restrictions		
Undesignated	347,170,734	327,644,303
Board-designated	527,628,588	463,799,743
With donor restrictions	419,721,291	444,015,707
Total net assets	1,294,520,613	1,235,459,753
Total liabilities and net assets	$1,514,228,400	$1,377,450,197

The accompanying notes are an integral part of these consolidated financial statements.

Cold Spring Harbor Laboratory

CONSOLIDATED STATEMENT OF ACTIVITIES

Year ended December 31, 2024
(with summarized financial information for the year ended December 31, 2023)

	Without Donor Restrictions	With Donor Restrictions	2024 Total	2023 Total
Revenue and other support				
Public support - contributions and nonfederal grant awards	$ 37,279,986	$ 30,053,970	$ 67,333,956	$ 114,454,836
Federal grant awards	34,649,686	-	34,649,686	35,774,511
Indirect cost allowances	35,917,132	-	35,917,132	33,311,621
Investment return utilized	40,315,350	-	40,315,350	39,546,774
Royalty and license revenue	8,933,978	-	8,933,978	18,445,260
Program fees	12,654,438	-	12,654,438	7,567,933
Publications sales	9,602,551	-	9,602,551	9,442,510
Dining services	6,086,817	-	6,086,817	5,335,060
Housing services	5,784,179	-	5,784,179	5,173,763
Miscellaneous	1,389,084	-	1,389,084	1,065,921
Net assets released from restrictions	54,028,609	(54,028,609)	-	-
Total revenue and other support	246,641,810	(23,974,639)	222,667,171	270,118,189
Expenses				
Research	117,036,335	-	117,036,335	113,153,717
Educational programs	21,450,546	-	21,450,546	20,906,758
Publications	10,180,220	-	10,180,220	10,571,538
Banbury Center conferences	2,899,318	-	2,899,318	2,513,128
DNA Learning Center programs	7,787,263	-	7,787,263	6,319,508
School of Biological Sciences programs	4,004,769	-	4,004,769	3,468,247
General and administrative	35,045,136	-	35,045,136	32,844,213
Total expenses	198,403,587	-	198,403,587	189,777,109
EXCESS (DEFICIENCY) OF REVENUE AND OTHER SUPPORT OVER EXPENSES	48,238,223	(23,974,639)	24,263,584	80,341,080
Other changes in net assets				
Investment return excluding amount utilized	30,283,358	19,009,130	49,292,488	68,305,764
Change in fair value of interest rate swap	4,833,695	-	4,833,695	397,646
Change in donor intent	-	(19,328,907)	(19,328,907)	-
INCREASE (DECREASE) IN NET ASSETS	83,355,276	(24,294,416)	59,060,860	149,044,490
Net assets at beginning of year	791,444,046	444,015,707	1,235,459,753	1,086,415,263
Net assets at end of year	$ 874,799,322	$ 419,721,291	$1,294,520,613	$1,235,459,753

The accompanying notes are an integral part of this consolidated financial statement.

Cold Spring Harbor Laboratory

CONSOLIDATED STATEMENT OF ACTIVITIES

Year ended December 31, 2023

	Without Donor Restrictions	With Donor Restrictions	2023 Total
Revenue and other support			
Public support - contributions and nonfederal grant awards	$ 45,688,095	$ 68,766,741	$ 114,454,836
Federal grant awards	35,774,511	-	35,774,511
Indirect cost allowances	33,311,621	-	33,311,621
Investment return utilized	39,546,774	-	39,546,774
Royalty and license revenue	18,445,260	-	18,445,260
Program fees	7,567,933	-	7,567,933
Publications sales	9,442,510	-	9,442,510
Dining services	5,335,060	-	5,335,060
Housing services	5,173,763	-	5,173,763
Miscellaneous	1,065,921	-	1,065,921
Net assets released from restrictions	43,040,442	(43,040,442)	-
Total revenue and other support	244,391,890	25,726,299	270,118,189
Expenses			
Research	113,153,717	-	113,153,717
Educational programs	20,906,758	-	20,906,758
Publications	10,571,538	-	10,571,538
Banbury Center conferences	2,513,128	-	2,513,128
DNA Learning Center programs	6,319,508	-	6,319,508
School of Biological Sciences programs	3,468,247	-	3,468,247
General and administrative	32,844,213	-	32,844,213
Total expenses	189,777,109	-	189,777,109
EXCESS OF REVENUE AND OTHER SUPPORT OVER EXPENSES	54,614,781	25,726,299	80,341,080
Other changes in net assets			
Investment return excluding amount utilized	39,540,565	28,765,199	68,305,764
Change in fair value of interest rate swap	397,646	-	397,646
INCREASE IN NET ASSETS	94,552,992	54,491,498	149,044,490
Net assets at beginning of year	696,891,054	389,524,209	1,086,415,263
Net assets at end of year	$ 791,444,046	$ 444,015,707	$1,235,459,753

The accompanying notes are an integral part of this consolidated financial statement.

Cold Spring Harbor Laboratory

CONSOLIDATED STATEMENTS OF CASH FLOWS

Years ended December 31,

	2024	2023
Cash flows from operating activities		
Increase in net assets	$ 59,060,860	$ 149,044,490
Adjustments to reconcile increase in net assets to net cash provided by operating activities:		
Change in fair value of interest rate swap	(4,833,695)	(397,646)
Depreciation and amortization	16,268,588	16,042,189
Net change in operating lease liability	91,587	(318,688)
Change in donor intent	19,328,907	-
Amortization of bond issuance costs	66,269	66,270
Net increase in fair value of investments	(75,739,773)	(93,096,715)
Contributions restricted for long-term investment or capital	(5,618,782)	(850,661)
Changes in assets and liabilities:		
Grants receivable	(1,986,239)	381,235
Contributions receivable, net	16,924,126	(29,126,241)
Restricted use assets	(74,398)	2,470,158
Other assets	119,668	(1,961,596)
Accounts payable and accrued expenses	(1,242,491)	1,892,217
Deferred revenue	(10,550,557)	(11,831,551)
Net cash provided by operating activities	11,814,070	32,313,461
Cash flows from investing activities		
Capital expenditures	(73,441,172)	(28,711,782)
Proceeds from sales and maturities of investments	215,157,469	185,800,136
Purchases of investments	(222,643,928)	(175,939,767)
Proceeds from sales and maturities of investments in certificate of deposits	123,422,951	69,493,502
Purchases of investments in certificate of deposits	(69,036,869)	(120,754,049)
Net change in investment in employee residences	(470,934)	(221,509)
Net cash used in investing activities	(27,012,483)	(70,333,469)
Cash flows from financing activities		
Contributions restricted for long-term investment	415,765	260,500
Contributions restricted for investment in capital	5,203,017	590,161
Decrease in contributions receivable	(2,598,130)	(3,086,227)
Proceeds from bonds payable	86,491,250	-
Debt issuance costs	(1,491,250)	-
Net cash provided by (used in) financing activities	88,020,652	(2,235,566)
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH	72,822,239	(40,255,574)
Cash and cash equivalents and restricted cash at beginning of year	36,912,401	77,167,975
Cash and cash equivalents and restricted cash at end of year	$ 109,734,640	$ 36,912,401
Reconciliation of cash and cash equivalents and restricted cash to the consolidated balance sheets		
Cash and cash equivalents, available for working capital	$ 18,404,777	$ 17,364,567
Cash and cash equivalents, board designated	24,961,115	19,547,834
Deposits with bond trustees	66,368,748	-
	$ 109,734,640	$ 36,912,401
Supplemental disclosures:		
Interest paid	$ 3,603,247	$ 3,581,394
Right of use asset acquired through an operating lease	$ 4,585,866	$ 310,300
Right of use asset acquired through a finance lease	$ 378,804	$ -
Purchases of capital expenditures in accounts payable	$ 7,067,343	$ 2,322,335
Operating cash flows from operating leases	$ 347,208	$ 337,095

The accompanying notes are an integral part of these consolidated financial statements.

NOTE 1 - DESCRIPTION OF BUSINESS

Discussion of Operations

Cold Spring Harbor Laboratory (the "Laboratory") is organized as an educational corporation under the laws of New York State. The Laboratory's primary objectives are to conduct research in cancer, neuroscience, genomics, quantitative biology and plant biology; to disseminate information; and to provide instruction and training through courses, meetings, publications, and a wide range of other educational activities.

The Laboratory, through its School of Biological Sciences ("SBS"), operates a graduate education program and confers the degrees of Doctor of Philosophy, Master of Science, and Doctor of Science, Honorary. These programs have been approved by the Board of Regents of the State of New York and the SBS is accredited by the New England Commission of Higher Education. Funding has been provided through the establishment of an endowment dedicated to the graduate school.

The consolidated financial statements of the Laboratory include two wholly-owned subsidiaries;

- Robertson Research Fund, Inc. ("Robertson") is a not-for-profit organization incorporated in Delaware in 1972 to provide funds for the benefit of the Laboratory on a continuing basis, unless the Laboratory ceases to be exempt from taxation under the Internal Revenue Code ("IRC"). Robertson is administered by a nine-member Board of Trustees, five of whom represent the Laboratory. The Laboratory is entitled to receive all of the income of Robertson. In years when the distribution has been less than the total annual income of the fund, the difference has been reinvested along with the principal of the fund to offset the effects of inflation and to provide for future programs at the Laboratory.

- Cold Spring Harbor Asia (SIP) Ltd. ("CSH Asia") is a wholly owned for-profit subsidiary established in Suzhou, People's Republic of China, in 2008. CSH Asia was created to expand the educational outreach of the Laboratory with the creation of a meetings and conferences program at a state-of-the-art conference center, owned by a private company, located in Suzhou. CSH Asia has an exclusive license to conduct scientific conferences and training courses in academic life sciences and applied biological sciences at the conference center. The license, originally a 10-year term expiring in 2018, was renewed for an additional 10-year term through December 31, 2028.

All intercompany accounts and transactions have been eliminated in consolidation.

Tax Status

The Laboratory and Robertson are exempt from federal income taxes under Section 501(c)(3) of the IRC. Accordingly, they are not subject to income taxes except to the extent there is taxable income from activities that are not related to their exempt purposes. CSH Asia was established as a taxable organization in China. The Laboratory receives income from unrelated activities, including advertising income on its journals and various alternative investment vehicles. The Laboratory recognizes the effects of income tax positions only if those positions are more likely than not of being sustained.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

These consolidated financial statements are prepared on the accrual basis of accounting in accordance with standards established by the Financial Accounting Standards Board ("FASB") for external financial reporting by not-for-profit organizations. Those standards require the classification of activities and net assets into two classes of net assets as follows:

Net assets without donor restrictions - Net assets that are not subject to donor-imposed restrictions, including the carrying value of all land, buildings, and equipment. Items that affect this net asset category include revenue and expenses associated with the primary objectives of the Laboratory, as well as gifts without restrictions, including those designated by the Board of Trustees of the Laboratory ("Trustees") to function as endowments. In addition, this category includes restricted gifts, whereby the gift receipt and fulfillment of donor-imposed restrictions occurred in the same year.

Net assets with donor restrictions - Net assets subject to donor-imposed restrictions that will be met by either the actions of the Laboratory or the passage of time. Expirations of donor restrictions on net assets are reported as net assets released from restrictions in the consolidated statements of activities. This category also includes net assets subject to donor-imposed restrictions to be maintained permanently by the Laboratory, the investment-related income from which is available to support research, education, and training. Realized and unrealized gains (losses) are added to (subtracted from) these net assets if so required by the donor. Absent specific donor requirements, gains are available to support research and educational activities.

Cash and Cash Equivalents

Cash and cash equivalents consist principally of short-term money market funds and certificates of deposits that mature in three months or less. Cash equivalents approximated $37,320,000 and $33,914,000 at December 31, 2024 and 2023, respectively.

Certificates of deposits that have a maturity of greater than three months are included in investments in certificates of deposits and are valued based on cost. The related accrued interest is reflected as interest receivables, which are included within cash and cash equivalents. As of December 31, 2024, all certificates of deposit will mature within one year and some are designated by the Trustees for the Foundations for the Future capital project, which is in progress.

As of December 31, 2024, restricted cash and cash equivalents includes deposits with bond trustees in the amount of $66,368,748.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. generally accepted accounting principles ("U.S. GAAP") requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingencies at the date of the consolidated financial statements, and revenue and expenses recognized during the reporting period. Actual results could differ from those estimates. Significant estimates and assumptions include the valuation of alternative investments, collectability of receivables, the interest rate swap liability, amortization of deferred revenue, the determination of medical and prescription benefit costs and related liability, and the allocation of expenses to functional classifications.

Fair Value Measurements

The Laboratory classifies its assets and liabilities measured at fair value into three levels based on the inputs used to measure them (see Note 5):

Level 1 - Quoted prices in active markets for identical assets or liabilities. Level 1 assets and liabilities include debt and equity securities that are traded in an active exchange market, as well as U.S. Treasury securities.

Level 2 - Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 2 assets and liabilities may include debt securities with quoted market prices that are traded less frequently than exchange-traded instruments. The Laboratory did not hold any Level 2 assets at December 31, 2024 or 2023.

Level 3 - Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. Level 3 assets and liabilities include financial instruments whose value is determined using pricing models, discounted cash flow methodologies, or similar techniques, as well as instruments for which the determination of fair value requires significant management judgment or estimation. This category generally includes certain private debt and equity instruments.

Fair value estimates are made at a specific point in time, based on available market information and judgments about the asset or liability, including estimates of timing, amount of expected future cash flows, and the credit standing of the issuer. In some cases, the fair value estimates cannot be substantiated by comparison to independent markets. In addition, the disclosed fair value may not be realized in the immediate settlement of the financial asset or the disclosed fair values do not reflect any premium or discount that could result from offering for sale at one time an entire holding of a particular financial asset. Potential taxes and other expenses that would be incurred in an actual sale or settlement are not reflected in amounts disclosed.

Investments

Investments are stated at fair value. Contributions of investment securities are recorded at their fair value at the date of the gift and are sold as soon as practicable following receipt. Publicly traded investments are valued at the last reported sales price on the date of valuation, as quoted on major securities exchanges. Securities that are not traded on major securities exchanges are valued based on quotations received from leading vendors.

Pooled investments include investments in limited partnerships, limited liability corporations, and offshore investment funds for the purpose of earning returns from alternative investment strategies. These investments are presented, under procedures established by the fund management, at net asset value or its equivalent, which generally represents the Laboratory's or Robertson's proportionate share of the net assets of the investment managers, as reported by them and reviewed by Laboratory management for reasonableness.

The proportionate share of fair value of investments may differ significantly, due to the inherent uncertainty of the valuations, from the values that would have been used had a ready market existed. The proportionate share of the change in fair values of the investment managers is recorded as an increase or a decrease in investment return, in other changes in net assets, in the consolidated statements of activities.

The Laboratory's investments include common and preferred stocks that do not have a readily determinable fair value which were received by the Laboratory from biotechnology companies in return for various rights to Laboratory developed intellectual property. Upon the receipt of founders stock from a newly formed company, the value of each share of stock is based on the amount paid per share by the outside investor(s). The amount is reduced by an appropriate valuation allowance, reflecting the high risk associated with start-up companies and limitations on the transferability of such stock, to arrive at the initial cost basis of the stock. The values of the stocks are not adjusted until either a) the company is determined to have no value, at which time the value of the stock is written off; b) the company is sold, at which time a gain or loss is recognized; or c) the company completes an initial public offering ("IPO") and its stock becomes publicly traded on a securities exchange. At the time of the IPO, the value of the stock is increased to fair value based on the quoted price of the stock. The fair value is reduced by an appropriate valuation allowance if the stock is restricted by governmental or contractual requirements or the Laboratory owns a large block of stock that could not be sold without potentially affecting the market price.

Contributions Receivable

Contributions receivable are recorded at their estimated net realizable value (discounted to present value at a risk-adjusted rate), less a reserve for bad debts.

Land, Buildings, and Equipment

Land, buildings, and equipment are reported at cost. Donated books and periodicals and other assets are recorded at appraised value as of the date of gift. Depreciation is computed on the straight-line basis over the estimated useful lives (ranging from three to forty years) of all buildings and equipment. Land, buildings, and equipment and other long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying value of the asset may not be recoverable. Long lived assets deemed to be permanently impaired are written down to fair value.

Interest Rate Swap

The Laboratory measures its derivative instrument (interest rate swap) at fair value. The fair value of the derivative held is based upon values provided by third-party financial institutions. It is not held for speculation purposes.

Deferred Revenue

On June 12, 2018, the Laboratory entered into a royalty purchase agreement for the right, title and interest in, and to, the future sales ("Purchased Receivables") associated with a drug created using patented Laboratory technology. The Laboratory received a $127,500,000 up-front payment. The payment was distributed in accordance with the Laboratory's commercial relations policy. The Laboratory deferred the recognition of the retained portion of the Purchase Receivables, which is being recognized over the life of the patent using the units of revenue method.

Future revenues require amortization for the period being calculated by computing a ratio of the proceeds received to the total payments expected to be made over the term of the agreement and then applying that ratio to the period's cash payment. The retained cash proceeds received from the investor were designated by the Trustees to function as an endowment, whereby the income generated from such funds will be used to support ongoing research programs. For the years ended December 31, 2024 and 2023, the Laboratory recognized $8,933,978 and $18,445,260, respectively, in royalty revenue pertaining to the Purchased Receivables.

A significant portion of the Laboratory's revenue is derived from cost-reimbursable contracts and grants, which are conditioned upon certain performance requirements and/or the incurrence of allowable qualifying expenses. If a contract or grant agreement is conditioned upon the achievement of certain significant milestones, the Laboratory will only recognize revenue to the extent those milestones or barriers have been achieved or overcome. Amounts received prior to meeting the milestones are reported as deferred revenue in the consolidated balance sheets. The Laboratory received advanced payments of approximately $168,000 and $1,640,000 for the years ended December 31, 2024 and 2023, respectively, recognized on the consolidated balance sheets as a deferred revenue. Deferred revenue also includes amounts received for publication subscriptions and fees received but not yet earned. Revenue is recognized in future periods as fees are earned and publications are shipped or made available to the subscriber.

Revenue

The Laboratory receives grants and contributions from a number of sources, including the federal government, foreign governments, private foundations, and other donors in support of its mission, which are awarded on a competitive basis. If there were a significant cutback in federal government research funding, it could have a material impact on the operations and cash flows of the Laboratory. The Laboratory recognizes government and private contracts and grants as either contributions or exchange transaction revenues, depending on whether the transaction is reciprocal or nonreciprocal. Unconditional grants and contributions, including promises to give cash and other assets, are reported at fair value at the date the contribution or grant is received. Conditional contributions, including conditional promises to give, are recognized when they become unconditional, that is, when the conditions, such as a barrier and right of return or release, are substantially met. Grants are evaluated as to whether they qualify as exchange transactions or contributions. Grants that are treated as exchange transactions are reported as revenue without donor restrictions when performance obligations within the terms of the agreement are met. The excess of amounts received in exchange transactions over revenue recognized are classified as deferred revenue on the consolidated balance sheets.

If a contract or grant agreement contains either a right of return or release to the grantor, as well as a barrier to be overcome, the Laboratory recognizes revenue for these conditional contributions when the barrier has been overcome. Funds received in advance of conditions being met are reported as deferred revenue within the accompanying consolidated balance sheets. At December 31, 2024 and 2023, the Laboratory had approximately $179,930,000 and $90,594,000, respectively, of conditional contributions that were awarded but not yet expended.

Indirect cost allowances recovered under certain government and other grants are accrued in the period the research and other services are performed. For federal grants, these accruals are based on an approved indirect cost rate negotiated with the cognizant government granting agency. In 2024, the Laboratory negotiated a new agreement establishing an unadjusted final rate for the year ended December 31, 2023 and establishing a provisional rate for the calendar years 2024 thru 2026. As required under the agreement, an indirect cost proposal for the year ended December 31, 2024 is due on June 30, 2025. The Laboratory believes that, except for changes in the federal regulations, the Laboratory should not be subject to a revision of its indirect cost rate through the end of 2025. For nongovernment grants, indirect cost recoveries are accrued at various rates as allowed by the grantor.

The Laboratory receives payments from customers for goods or services associated with its educational programs offered through its Banbury Conference Center, DNA Learning Center, and the Meetings and Courses division. These programs generate revenues through program fees, publications sales, dining services, and housing services. The Laboratory recognizes revenue when control of promised goods or services are transferred to outside parties in an amount that reflects the consideration the Laboratory expects to be entitled to in exchange for those goods or services.

Royalty and License Revenue

Royalty and license revenues result from the transfer of intellectual property rights developed by Laboratory employees. In accordance with the Laboratory's policy, royalty and license revenues are distributed to the inventor, author or collaborator, and the Laboratory using an income sharing formula. The portion retained and recognized by the Laboratory is recorded as revenue on the consolidated statements of activities.

Allocation of Expenses on a Functional Basis

Expenses are reported in the consolidated statement of activities by their programmatic classifications. The Laboratory's primary program services are research, education and publications. Expenses reported as general and administrative are incurred in support of these primary program services.

The Laboratory allocates certain types of expenses that relate to more than one program or supporting activity. Expenses of this nature include, but are not limited to, depreciation, interest, operations and maintenance of plant, library, direct research support, and information technology. Amounts have been allocated to the specific programs and support services using methods such as square footage, usage, and other financial methods determined by management and are consistently applied.

Measure of Operations

The Laboratory includes in its definition of operations all revenues and expenses associated with its primary program services are research, education and publications. Investment return excluding amounts utilized, change in fair value of the interest rate swap agreement, and changes in donor intent are excluded from the measure of operations.

Reclassifications

Certain amounts from the 2023 consolidated financial statements have been reclassified to conform to the 2024 presentation. However, there was no impact on total assets, liabilities, net assets, revenues, or expenses as a result of these reclassifications.

NOTE 3 - LIQUIDITY AND AVAILABILITY OF FINANCIAL RESOURCES

The Laboratory regularly monitors the availability of resources required to meet operating needs and other contractual commitments, while also striving to maximize the investment of its available funds. For purposes of analyzing resources available to meet general expenditures over a 12-month period, the Laboratory considers all expenditures related to its ongoing activities of research, educational programs and publications, as well as the services to support those activities.

The Laboratory's Trustees have designated a portion of its net assets without donor restrictions for endowment and other purposes. These amounts are identified as Board-designated funds. These funds are invested for long-term appreciation and current income but remain available and may be spent at the discretion of the Trustees.

In addition to financial assets available to meet general expenditures over the next 12 months, the Laboratory operates with a balanced budget and anticipates collecting sufficient revenue, including federal funds, to cover general expenditures not covered by donor-restricted resources. The Laboratory typically generates positive cash flows from operations, as evidenced by the consolidated statements of cash flows for 2024 and 2023.

As of December 31, 2024 and 2023, financial assets and liquidity resources available within one year for general expenditure were as follows:

	2024	2023
Liquidity/financial assets, net of certain items with donor restrictions:		
Cash and cash equivalents	$ 18,065,412	$ 16,648,491
Grants receivable, net	11,265,142	9,278,903
Contributions receivable due within one year	24,012,523	13,251,292
Investments available for general expenditure	40,763,658	26,275,941
Total liquidity/financial assets	$ 94,106,735	$ 65,454,627

In addition to these resources, the Laboratory's liquidity strategy includes board-designated quasi-endowment funds and other instruments totaling $527,628,588 and $463,799,743 on December 31, 2024 and 2023, respectively. Spending from these funds, although not currently contemplated, is possible with authorization from the board of trustees.

NOTE 4 - INVESTMENTS

The fair value of investments at December 31 is as follows:

	2024	2023
Mutual funds:		
Money market	$ 87,222,148	$ 96,844,737
Large/mid cap growth	139,719,942	107,833,933
Diversified fixed income	18,914,730	25,868,837
Stocks - domestic	740,509	767,016
Alternative investments:		
Multi-strategy, fund of funds, and absolute return	138,581,840	123,073,316
Long/short equity	267,720,478	256,336,348
Global/international equity	158,013,779	122,819,570
Emerging markets	-	16,494,722
Private investments	11,826,732	12,275,447
Subscriptions in transit	26,800,000	-
Investment redemption receivable	-	4,000,000
	$ 849,540,158	$ 766,313,926

Money market mutual funds represent cash held for investment on a short-term basis as part of the investment portfolio, which are invested at the direction of the Investment Committees of the Laboratory or of Robertson, as applicable.

Stocks include publicly traded common stock holdings in domestic organizations. Also included are the Laboratory's investments in common and preferred stock holdings in biotechnology companies principally received for Laboratory-developed intellectual property, as discussed in Note 2. The biotechnology companies have a fair value of approximately $168,000 and $494,000 at December 31, 2024 and 2023, respectively, net of a valuation allowance of approximately $1,735,000 and $1,744,000 at December 31, 2024 and 2023, respectively, on the shares that do not have a readily determinable fair value.

The Laboratory submitted a redemption request relative to an investment fund, which remained outstanding as of December 31, 2023. This redemption receivable was collected in full in 2024. In addition, the Laboratory initiated subscriptions for new investments totaling $26,800,000 that were in transit as of December 31, 2024.

The alternative investment portfolio includes limited partnerships, limited liability corporations, and offshore investment funds. The underlying investments include, among other financial instruments, futures and forward contracts, options, and securities sold but not yet purchased, intended to hedge against changes in the market value of investments. These financial instruments involve varying degrees of off-balance sheet risk. All investments are exposed to some risk including interest rate, market, and credit risks. Due to the level of risk associated with certain investments, it is at least reasonably possible that changes in the values of investments will occur in the near term and such changes could materially affect the consolidated financial statements.

Alternative investments are diversified across five basic investment strategies as follows:

Multi-strategy, fund of funds, and absolute return - represent investments in a broad range of investment strategies that seek to exploit opportunities as they occur in the markets due to temporary dislocations or structural inefficiencies. This category includes managers that utilize a fund of funds philosophy.

Long/short equity - primarily investments in funds that, in turn, invest in liquid marketable securities, attempting to realize gains through the identification of mispriced securities, involving buying long equities that are expected to increase in value and selling short equities that are expected to decrease in value.

Global/international equity - consists of investments in both growth and value-oriented equity securities of companies located outside the United States. Investment instruments include convertible investment grade securities, options, warrants, physical currencies, spot and forward currency contracts.

Emerging markets - an absolute return focused investment in debt and equity securities in emerging markets. Debt securities include both dollar-denominated and local currency sovereign debt, corporate debt, and inflation-protected securities.

Private investments - consists of investments in private funds, including buyouts and growth capital, international private equity, and other stressed and distressed opportunities. At December 31, 2024, the Laboratory had outstanding commitments to private investment managers totaling $27,691,557.

Alternative investments contain various redemption restrictions with required written notice ranging from five to seventy-five days. In addition, certain of these investments are restricted by initial lockup periods.

The composition of the alternative investments by their various redemption provisions and lockup periods as of December 31, 2024 and 2023 are as follows:

Redemption Frequency	2024	2023
Weekly to one month	$ 283,769,158	$ 255,864,626
Two to three months	71,505,093	74,711,177
Semi-annual	62,717,090	51,883,316
Annual	91,035,084	79,713,842
One to two years	55,276,778	56,538,102
No redemptions	11,839,626	12,288,340
	$ 576,142,829	$ 530,999,403

NOTE 5 - FAIR VALUE OF FINANCIAL ASSETS

The following tables present the Laboratory's fair value hierarchy for those assets measured at fair value on recurring basis as of December 31:

	2024			
Financial Assets	Total	Level 1	Level 2	Level 3
Investments:				
Mutual funds:				
Money market	$ 87,222,148	$ 87,222,148	$ -	$ -
Large/mid cap growth	139,719,942	139,719,942	-	-
Diversified fixed income	18,914,730	18,914,730	-	-
Stocks - domestic	740,509	572,954	-	167,555
Investments at net assets value ("NAV"):				
Alternative investments				
Multi-strategy, fund of funds, and absolute return	138,581,840	-	-	-
Long/short equity	267,720,478	-	-	-
Global/international equity	158,013,779	-	-	-
Private investments	11,826,732	-	-	-
Subscriptions in transit	26,800,000	-	-	-
Total investments	849,540,158	246,429,774	-	167,555
Investment in employee residences	7,280,837	-	-	7,280,837
Limited liability partnership [1]	246,000	-	-	246,000
Total	$ 857,066,995	$ 246,429,774	$ -	$ 7,694,392

[1] Included in other assets on the consolidated balance sheets.

	2023			
Financial Assets	Total	Level 1	Level 2	Level 3
Investment in trust assets [1]	$ 19,328,907	$ -	$ -	$ 19,328,907
Investments:				
Mutual funds:				
Money market	96,844,737	96,844,737	-	-
Large/mid cap growth	107,833,933	107,833,933	-	-
Diversified fixed income	25,868,837	25,868,837	-	-
Stocks - domestic	767,016	273,230	-	493,786
Investments at net assets value ("NAV"):				
Alternative investments				
Multi-strategy, fund of funds, and absolute return	123,073,316	-	-	-
Long/short equity	256,336,348	-	-	-
Global/international equity	122,819,570	-	-	-
Emerging markets	16,494,722	-	-	-
Private investments	12,275,447	-	-	-
Investment redemption receivable	4,000,000	-	-	-
Total investments	766,313,926	230,820,737	-	493,786
Investment in employee residences	6,809,903	-	-	6,809,903
Limited liability partnership [2]	246,000	-	-	246,000
Total	$ 792,698,736	$ 230,820,737	$ -	$ 26,878,596

[1] Included in contributions receivable on the consolidated balance sheets.
[2] Included in other assets on the consolidated balance sheets.

NOTE 6 - CONTRIBUTIONS RECEIVABLE, NET

Contributions receivable, net, consist of the following at December 31:

	2024	2023
Contributions receivable	$ 102,963,066	$ 136,974,856
In-kind receivable	18,837,126	19,598,222
	121,800,192	156,573,078
Less: discount to present value at rates ranging from 0.24% to 4.72%	(14,798,576)	(15,686,899)
Reserve for uncollectible pledges	(1,423,590)	(1,653,250)
Contributions receivable, net	$ 105,578,026	$ 139,232,929

Contributions receivable are expected to be collected as follows:

	2024	2023
Within one year	$ 24,012,523	$ 41,000,665
One to five years	67,175,814	65,736,035
More than five years	30,611,855	49,836,378
	$ 121,800,192	$ 156,573,078

Unconditional promises to give are recognized initially at fair value as contributions revenue in the period such promises are made by donors. Fair value is estimated giving consideration to anticipated future cash receipts (after an allowance is made for uncollectible contributions) and discounting such amounts at a risk-adjusted rate commensurate with the duration of the donor's payment plan. In subsequent periods, the discount rate is unchanged and the allowance for uncollectible contributions is reassessed and adjusted if necessary. Amortization of the discounts is recorded as additional contribution revenue. Contributions receivable at December 31, 2024 included thirty-nine individual pledges, six of which represent approximately 59% of the amount due, with a total of $30 million due from a single donor, and $60 million due from Trustees. Contributions receivable at December 31, 2023 included forty-three individual pledges, seven of which represent approximately 70% of the amount due, with a total of $44 million due from a single donor, and $80 million due from Trustees.

A donor had established and funded a gift instrument which was administered by the donor's investment firm. Under the original terms of the agreement, the Laboratory did not control the assets; however, it held an irrevocable right to receive all the assets of the gift at the expiration of the agreement in 2040. For the year ended December 31, 2023, the Laboratory recorded the value of the assets as increases in net assets with donor restrictions at the fair value of the assets. The change in fair value reported for the year ended December 31, 2023 was $3,121,769. In March 2024, the agreement was amended and replaced in its entirety. Under the revised terms, the donor intends to provide future annual grants based on a percentage of the donor's established grant fund. As a result of this amendment, during the year ended December 31, 2024, the Laboratory removed the previously recognized assets from the consolidated balance sheet and recorded a change in donor intent totaling $19,328,907.

Also included in contributions receivable is the Laboratory's interest in charitable remainder unitrusts. In accordance with the terms of the trusts, the Laboratory will receive a defined interest upon the death of the designated beneficiaries. The Laboratory's interest, net of the present value discount, approximated $12,698,000 and $10,688,000 at December 31, 2024 and 2023, respectively.

On October 1, 2019, the Laboratory entered into a lease agreement with a third-party to open the DNA Learning Center at City Tech in Brooklyn, New York. The agreement provides for the Laboratory to make below market rental payments through September 30, 2049. The Laboratory is recording the lease as an in-kind pledge receivable. For the years ended December 31, 2024 and 2023, the net fair market value of the in-kind lease pledge is valued at $11,588,274 and $11,866,797, respectively.

For the years ended December 31, 2024 and 2023, the Laboratory recognized a contributed nonfinancial asset of approximately $483,000 and $493,000, respectively, for the below market rental payments on the DNA Learning Center. Unless otherwise noted, contributed nonfinancial assets did not have donor-imposed restrictions. The contributed use of the DNA Learning Center will be utilized for Laboratory educational programs. In valuing the below market rental payments, the Laboratory estimated the fair value on the basis of comparable rental values with the same geographic area.

NOTE 7 - RESTRICTED USE ASSETS

Restricted use assets principally include a supplemental executive retirement plan ("SERP") established by the Laboratory for certain members of its management and scientific staff. The Laboratory has established a grantor trust, whereby the assets and income of the trust are assets and income of the Laboratory. At December 31, 2024 and 2023, the fair value of the assets in the trust was $138,840 and $94,566, respectively.

NOTE 8 - INVESTMENT IN EMPLOYEE RESIDENCES

Investment in employee residences consists of (a) notes receivable collateralized by mortgages on residential properties owned by several senior employees; and (b) the Laboratory's percentage ownership in residences inhabited by employees. Upon sale of these residences, the Laboratory will either share in market value fluctuations of the real estate in proportion to its ownership in the residence or receive reimbursement of the outstanding mortgage balance. These investments were authorized by the Trustees to enable such employees to purchase local residences. All costs of property ownership, including real estate taxes, are borne by the employees.

NOTE 9 - LAND, BUILDINGS, AND EQUIPMENT

Land, buildings, and equipment at December 31 consist of the following:

	2024	2023
Land and land improvements	$ 33,010,703	$ 32,160,028
Buildings	369,845,249	367,727,899
Furniture, fixtures and equipment	22,854,952	20,200,672
Laboratory equipment	55,501,288	51,820,445
Library books and periodicals	365,630	365,630
Construction in progress	110,778,930	45,973,043
	592,356,752	518,247,717
Less: accumulated depreciation and amortization	(211,821,376)	(199,879,542)
Land, buildings and equipment, net	$ 380,535,376	$ 318,368,175

During the years ended December 31, 2024 and 2023, the Laboratory wrote off approximately $4,000,000 and $46,000,000, respectively, of fully depreciated fixed assets. As a result, the respective asset and associated accumulated depreciation balances were appropriately reduced.

Construction in progress at December 31, 2024 represents the cost of various campus renovations ongoing at the Laboratory, of which, one is a large multi-year construction project. The large multi-year project is the Foundations for the Future project, which is a major expansion adding multiple buildings to the campus to support the research, education and housing programs. There was approximately $104 million and $43 million included in construction in progress for this project at December 31, 2024 and 2023, respectively.

At December 31, 2024, amounts committed for construction contracts were approximately $112,200,000.

NOTE 10 - BONDS PAYABLE

Bonds payable at December 31 consist of the following:

	Maturity	Interest	2024	2023
Nassau County Industrial Development Agency ("NCIDA") Bonds, Series 1999. [(a)]	2034	4.05%	$ 42,200,000	$ 42,200,000
NCIDA Bonds, Series 2006. [(b)]	2029	3.80%	55,000,000	55,000,000
Nassau County Local Economic Assistance Corporation ("NCLEAC") Bonds, Series 2024A. [(c)]	2030, 2032	5.00%	44,915,000	-
NCLEAC Bonds, Series 2024B [(c)]	2045	3.65%	35,665,000	-
			177,780,000	97,200,000
Plus: premium on bond			5,754,620	-
Less: bond issuance costs			(2,458,505)	(1,060,959)
			$ 181,076,115	$ 96,139,041

[(a)] On April 1, 1999, the Laboratory issued $42.2 million of bonds through the Nassau County Industrial Development Agency ("NCIDA"). Approximately $15 million of the proceeds were used to finance the purchase and renovation of a building located in Woodbury, New York and the remaining $27 million of the proceeds were used to refund prior bond issues. The bonds require principal payments only at maturity on January 1, 2034; bear interest at a variable daily rate, which is payable on a monthly basis (4.05% and 3.90% as of December 31, 2024 and 2023, respectively); and are secured by a liquidity facility agreement issued by a financial institution scheduled to expire on June 24, 2026. The interest rate is negotiated with the bondholders by the remarketing agent.

[(b)] On June 27, 2006, the Laboratory issued $55 million of bonds through the NCIDA for the purpose of paying a portion of the cost of construction, installation, and equipping of seven new research buildings and creating 120,000 square feet of space, on the Laboratory's main campus in Laurel Hollow. On April 2, 2020, the entire outstanding principal amount was purchased by a single financial institution under an agreement that was due on June 19, 2025, unless extended. On October 31, 2024, the Laboratory amended the agreement to extend the maturity date to October 31, 2029. The bonds bear interest at a fixed percent of the sum of the federal funds rate (reported daily as H.15), plus a spread. Upon termination of the agreement, the bonds may thereafter be converted in whole or in part to bear interest at any of the acceptable rates of interest under the bond documents until maturity on January 1, 2042. The bonds require annual principal payments beginning January 1, 2035 through maturity at amounts between $6 million to $8 million. Interest is payable the first business day of each month, (3.80% and 4.32% as of December 31, 2024 and 2023, respectively).

[(c)] On October 31, 2024, the Nassau County Local Economic Assistance Corporation ("NCLEAC") issued $80,580,000 in Revenue Bonds on behalf of the Laboratory, consisting of $44,915,000 Series 2024A Bonds (Fixed Rate) and $35,665,000 Series 2024B Bonds (Variable Rate Demand Bonds). The proceeds are being used to finance the construction of four new research buildings and a parking garage, renovations to existing facilities, and to pay costs of issuance. The Series 2024A Bonds bear interest at fixed rates and mature in 2030 and 2032, while the Series 2024B Bonds bear variable weekly

interest and mature on January 1, 2045. The Series 2024B Bonds are supported by a Standby Bond Purchase Agreement with TD Bank, N.A., expiring October 31, 2029. Premiums paid at issuance of the Series 2024A Bonds totaled $5,911,250 ($5,754,620 unamortized at December 31, 2024).

The agreements contain certain covenants, including those relating to net worth as defined, restrictions of additional liens on certain Laboratory property, and assumption of additional debt. The Laboratory was in compliance with the required covenants as of December 31, 2024 and 2023.

The Laboratory has an interest rate swap agreement with a notional principal amount of $97.2 million associated with the Series 1999 and Series 2006 bond issues. The swap agreement had an effective date of October 1, 2006 and a termination date of January 1, 2042. On October 18, 2018, the swap agreement was amended, and the Laboratory now pays interest at a predetermined fixed rate of 3.80% and receives 68% of the federal funds rate (reported daily as H.15), plus a spread on the notional principal amount.

The fair value of the interest rate swap was a liability of $7,355,377 and $12,189,072 at December 31, 2024 and 2023, respectively. The fair value of the interest rate swap was determined using pricing models developed based on the federal funds rate and other observable market data (Level 2 inputs). The change in fair value is reported as other changes in net assets in the accompanying consolidated statements of activities. According to the agreement with JPMorgan Chase Bank, N.A., when the fair value of the liability exceeds $40 million, the Laboratory is required to post collateral equal to the amount in excess.

Financing costs incurred in connection with the bond issues were reported as a direct deduction of the face amount of the related bond and are amortized over the life of the bonds. Unamortized financing costs were $2,458,505 and $1,060,959 at December 31, 2024 and 2023, respectively.

For the year ended December 31, 2024, interest incurred (and the associated effective rate) on outstanding bonds was approximately $3,974,000 (2.24%), of which $3,561,300 was recognized as expense and $412,700 was capitalized as construction in progress. Interest expense (and the associated effective rate) on bonds outstanding during 2023 was approximately $3,590,300 (3.69%).

NOTE 11 - NET ASSETS WITH DONOR RESTRICTIONS

Net assets with donor restrictions at December 31 are available for the following purposes or periods as follows:

	2024	2023
Net assets with specific purpose or time restrictions:		
Capital projects	$ 4,759,425	$ 163,981
Research programs	5,234,375	15,212,619
Educational programs	13,278,276	13,458,323
Time-restricted	78,731,519	97,559,076
Total with specific purpose or time restrictions	102,003,595	126,393,999
Endowments subject to the Laboratory's spending policy:		
Donor contributions to be maintained in perpetuity:		
Primary program services	76,024,384	75,608,619
School of Biological Sciences programs	42,340,600	42,340,600
Operation and improvement of Banbury Center facilities	1,511,804	1,511,804
Total donor contributions to be maintained in perpetuity	119,876,788	119,461,023
Accumulated income on endowment funds pending appropriation:		
Primary program services	154,956,461	160,408,209
School of Biological Sciences programs	24,417,621	20,406,871
Operation and improvement of Banbury Center facilities	18,466,826	17,345,605
Total income on endowment funds	197,840,908	198,160,685
Total endowment subject to appropriation under the Laboratory's spending policy	317,717,696	317,621,708
Total net assets with donor restrictions	$ 419,721,291	$ 444,015,707

The following table summarizes the net assets released from restrictions for the years ended December 31:

	2024	2023
Purpose restrictions met	$ 19,700,159	$ 14,008,187
Time restriction expires	34,328,450	29,032,255
	$ 54,028,609	$ 43,040,442

NOTE 12 - INVESTMENT RETURN UTILIZED

Investment return utilized includes amounts appropriated from donor-restricted endowment funds, as reported in Note 13, and investment return on working capital funds. The following tables summarize the Laboratory's total investment return for the years ended December 31:

	2024		
	Without Donor Restrictions	With Donor Restrictions	Total
Net investment income	$ 10,501,424	$ 1,401,148	$ 11,902,572
Net appreciation of investments	60,097,284	17,607,982	77,705,266
Total net investment gain	70,598,708	19,009,130	89,607,838
Investment return utilized in operations	(40,315,350)	-	(40,315,350)
Excess investment return over endowment spending formula	$ 30,283,358	$ 19,009,130	$ 49,292,488

	2023		
	Without Donor Restrictions	With Donor Restrictions	Total
Net investment income	$ 8,886,796	$ 800,819	$ 9,687,615
Net appreciation of investments	70,200,543	27,964,380	98,164,923
Total net investment gain	79,087,339	28,765,199	107,852,538
Investment return utilized in operations	(39,546,774)	-	(39,546,774)
Excess investment return over endowment spending formula	$ 39,540,565	$ 28,765,199	$ 68,305,764

NOTE 13 - ENDOWMENT FUNDS

The Laboratory's endowment (including Robertson) consists of approximately 180 individual funds established for a variety of purposes and includes both donor-restricted endowment funds and funds without donor restrictions designated by the Trustees to function as endowments. The Laboratory's management and investment of donor-restricted endowment funds are governed by the New York Prudent Management of Institutional Funds Act ("NYPMIFA"). The Laboratory has interpreted the law as not requiring the preservation of the fair value of the original gift as of the gift date of the donor-restricted endowment funds absent explicit donor stipulations to the contrary. As a result of this interpretation, the Laboratory classifies as endowment funds within net assets with donor restrictions (a) the original value of gifts donated to the endowment, (b) the original value of subsequent gifts to the endowment, and (c) accumulations to the endowment made in accordance with the explicit direction of the applicable donor gift instrument at the time the accumulation is added to the fund. The remaining portion of the net assets with donor restrictions within the endowment fund are those net assets that have not yet been appropriated for expenditure by the Laboratory in a manner consistent with the standard of prudence prescribed by NYPMIFA.

The Laboratory's investment policy for its endowment and similar funds emphasizes long-term capital appreciation as a primary source of return while balancing the dual objectives of growth in capital and principal preservation. Investments are expected to earn long-term returns sufficient to maintain or grow the purchasing power of assets, net of spending and investment expenses, within acceptable risk parameters. The portfolio is invested in domestic and international equities, private, and other nontraditional investments, broadly diversified fixed income and cash equivalents. The portfolio is expected to earn returns higher than the "market" as represented by a benchmark constructed as a blended rate of indices. The portfolio oversight rests with the Investment Committees of the Laboratory and Robertson, including the selection of external managers, the allocation of investments, and the type of investments.

The following factors are considered in making a determination to appropriate or accumulate donor-restricted endowment funds:

1 The duration and preservation of the fund
2 The purposes of the Laboratory and the donor-restricted endowment fund
3 General economic conditions
4 The possible effect of inflation or deflation
5 The expected total return from income and the appreciation of investments
6 Other resources of the Laboratory
7 Where appropriate and circumstances would otherwise warrant, alternatives to expenditure
8 The investment policies of the Laboratory

In accordance with the spending policies of the Laboratory and Robertson, the Trustees authorized a 4.5% spend-down on endowment funds based on a 12-quarter moving average of the market value of endowment investments. If interest, dividends, and gains are not sufficient to support the current year drawdown, the balance is provided from prior year earnings. If investment return is in excess of the authorized spending level, the balance is reinvested to compound future earnings potential.

In accordance with the above spending, $32,796,940 and $31,894,194 were made available to support operations of the Laboratory in 2024 and 2023, respectively. The total planned appropriation for expenditure for 2025 is approximately $34,900,000.

From time to time, the fair value of assets associated with individual donor-restricted endowment funds may fall below the level that the donor or NYPMIFA requires the Laboratory to maintain as a fund of perpetual duration. In accordance with U.S. GAAP, deficiencies of this nature are reported in net assets with donor restrictions and totaled $737,616 and $1,128,162 at December 31, 2024 and 2023, respectively. These deficiencies resulted from unfavorable market fluctuations that occurred shortly after the investment of new donor-restricted contributions and continued appropriation for certain programs that was deemed prudent by the Trustees.

The following table presents endowment net asset composition by type of fund as of December 31:

	2024				
		With Donor Restrictions			
	Without Donor Restrictions	Original Gift	Accumulated Gains (Losses)	Total	Total Endowment Funds
Donor-restricted:					
Underwater	$ -	$ 7,583,325	$ (737,616)	$ 6,845,709	$ 6,845,709
Other	-	112,293,463	198,578,525	310,871,988	310,871,988
Board-designated	527,628,588	-	-	-	527,628,588
Total endowment funds	$ 527,628,588	$ 119,876,788	$ 197,840,909	$ 317,717,697	$ 845,346,285

The following table presents the changes in endowment net assets for the year ended December 31:

	2024		
	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at beginning of year	$ 463,799,743	$ 317,621,708	$ 781,421,451
Net investment income	4,095,691	1,401,149	5,496,840
Net appreciation (realized and unrealized)	58,984,606	17,607,982	76,592,588
Total investment return	63,080,297	19,009,131	82,089,428
Transfers and contributions	33,545,488	415,765	33,961,253
Change in donor intent	-	(19,328,907)	(19,328,907)
Appropriation of endowment assets for expenditure	(32,796,940)	-	(32,796,940)
Endowment net assets at end of year	$ 527,628,588	$ 317,717,697	$ 845,346,285

Included in amounts above is approximately $300 thousand in pledges receivable.

	2023				
		With Donor Restrictions			
	Without Donor Restrictions	Original Gift	Accumulated Gains (Losses)	Total	Total Endowment Funds
Donor-restricted:					
Underwater	$ -	$ 7,249,387	$ (1,128,162)	$ 6,121,225	$ 6,121,225
Other	-	112,211,636	199,288,847	311,500,483	311,500,483
Board-designated	463,799,743	-	-	-	463,799,743
Total endowment funds	$ 463,799,743	$ 119,461,023	$ 198,160,685	$ 317,621,708	$ 781,421,451

The following table presents the changes in endowment net assets for the year ended December 31:

	2023		
	Without Donor Restrictions	With Donor Restrictions	Total
Endowment net assets at beginning of year	$ 410,037,211	$ 288,596,004	$ 698,633,215
Net investment income	2,237,263	800,825	3,038,088
Net appreciation (realized and unrealized)	69,197,497	27,964,379	97,161,876
Total investment return	71,434,760	28,765,204	100,199,964
Transfers and contributions	14,221,966	260,500	14,482,466
Appropriation of endowment assets for expenditure	(31,894,194)	-	(31,894,194)
Endowment net assets at end of year	$ 463,799,743	$ 317,621,708	$ 781,421,451

Included in amounts above is approximately $19.7 million in pledges receivable.

NOTE 14 - EXPENSE CLASSIFICATIONS

Expenses are reported in the accompanying consolidated statements of activities by their program classifications. The Laboratory's primary program services are research, education, and publications. Expenses reported as general and administrative are incurred in support of these primary program services.

The Laboratory allocates certain types of expenses that relate to more than one program or supporting activity. Expenses of this nature include, but are not limited to, depreciation, interest, operations and maintenance of plant, library, direct research support, and information technology. Amounts have been allocated to the specific programs and support services using methods such as square footage, usage, and other financial methods determined by management and are consistently applied.

	2024			2023		
	Direct Program Expenses	Allocated Expenses	Total	Direct Program Expenses	Allocated Expenses	Total
Research	$ 73,986,354	$ 43,049,981	$ 117,036,335	$ 72,088,806	$ 41,064,911	$ 113,153,717
Educational programs	16,603,362	4,847,184	21,450,546	16,353,178	4,553,580	20,906,758
Publications	9,274,947	905,273	10,180,220	9,533,128	1,038,410	10,571,538
Banbury Center conferences	1,462,626	1,436,692	2,899,318	1,180,260	1,332,868	2,513,128
DNA Learning Center programs	6,344,348	1,442,915	7,787,263	4,950,857	1,368,651	6,319,508
SBS programs	4,000,909	3,860	4,004,769	3,464,387	3,860	3,468,247
General and administrative	27,724,295	7,320,841	35,045,136	26,564,007	6,280,206	32,844,213
	$ 139,396,841	$ 59,006,746	$ 198,403,587	$ 134,134,623	$ 55,642,486	$ 189,777,109

The following table represents functional expenses by natural category reported for research, educational, and publication, general and administrative and fundraising categories, including direct conduct or management of those programs. Included in general and administrative costs are all other unallocated costs associated with administration, accounting, human resources, sponsored programs, communications and dining. The salary and benefits of the chief executive officer are allocated 50% to research programs, 40% to general and administrative costs and 10% to fundraising based on estimated time and effort throughout the year. These allocations are determined by management to be of a reasonable basis and are consistently applied.

The following table presents the functional expenses for the year ended December 31, 2024:

	Research	Educational Programs/ Conferences	Publications	General and Administrative	Fundraising	Total
Salaries, benefits and taxes	$ 63,753,049	$ 17,152,898	$ 5,586,716	$ 22,229,346	$ 1,693,173	$ 110,415,182
Supplies and office expense	18,472,538	3,766,968	128,242	2,393,041	51,648	24,812,437
Third party costs	4,514,319	-	-	-	-	4,514,319
Service contracts and repairs	3,239,202	726,724	65,701	499,869	-	4,531,496
Professional services	1,396,212	2,177,821	433,956	2,032,455	48,100	6,088,544
Printing and publications	1,668,217	303,651	2,522,326	126,017	36,814	4,657,025
Software licensing	1,671,036	729,617	179,256	377,584	-	2,957,493
Travel	725,315	1,548,251	80,782	73,946	4,562	2,432,856
Conferences	422,778	3,810,313	440	22,143	1,325	4,256,999
Occupancy	5,222,928	2,665,450	211,006	949,274	-	9,048,658
Interest	2,857,286	230,913	93,009	638,748	-	3,819,956
Depreciation	11,609,486	2,444,703	147,530	2,066,869	-	16,268,588
Miscellaneous	1,483,969	584,587	731,256	1,772,328	27,894	4,600,034
	$ 117,036,335	$ 36,141,896	$ 10,180,220	$ 33,181,620	$ 1,863,516	$ 198,403,587
Percentage of total expense	59.0%	18.2%	5.2%	16.7%	0.9%	100%

The following table presents the functional expenses for the year ended December 31, 2023:

	Research	Educational Programs/ Conferences	Publications	General and Administrative	Fundraising	Total
Salaries, benefits and taxes	$ 58,790,046	$ 15,002,709	$ 5,334,023	$ 19,558,513	$ 1,606,352	$ 100,291,643
Supplies and office expense	19,568,743	3,972,967	161,873	2,026,039	41,051	25,770,673
Third party costs	6,140,824	-	-	-	-	6,140,824
Service contracts and repairs	3,522,349	1,064,491	72,907	489,363	-	5,149,110
Professional services	1,532,955	1,917,650	422,886	3,231,647	48,228	7,153,366
Printing and publications	1,444,964	172,463	2,945,935	200,103	19,391	4,782,856
Software licensing	1,242,444	494,015	116,030	273,611	63	2,126,163
Travel	586,253	1,066,948	96,745	62,912	5,005	1,817,863
Conferences	350,533	3,684,243	337	19,097	185	4,054,395
Occupancy	4,840,224	2,543,032	270,503	844,638	-	8,498,397
Interest	2,846,135	230,099	92,765	636,475	-	3,805,474
Depreciation	11,505,801	2,382,587	191,355	1,962,446	-	16,042,189
Miscellaneous	782,446	676,437	866,179	1,771,249	47,845	4,144,156
	$ 113,153,717	$ 33,207,641	$ 10,571,538	$ 31,076,093	$ 1,768,120	$ 189,777,109
Percentage of total expense	59.6%	17.5%	5.6%	16.4%	0.9%	100%

NOTE 15 - RETIREMENT PLAN

The Laboratory's employees are covered under a defined contribution retirement plan (the "Plan"). The Laboratory remits contributions to the Plan at Fidelity Investments based on a predetermined percentage of the participants' salaries. Total contributions under the Plan approximated $5,508,500 and $5,111,500 for the years ended December 31, 2024 and 2023, respectively.

NOTE 16 - COMMITMENTS AND CONTINGENCIES

The Laboratory had an operating lease for office space at 50 Gordon Drive, Syosset, New York. The lease did not contain any material residual value guarantees or material restrictive covenants. As of December 1, 2024, this lease has ended and there was no subsequent renewal or extension. The right-of-use asset and lease liability were recognized at the lease commencement date based on the present value of the lease payments over the lease term. A risk adjusted rate of 2.69% was used to determine the present value of the lease payments, which are recognized on a straight-line basis over the lease term. The operating lease cost was approximately $324,400 and $299,200 for the years ended December 31, 2024 and 2023, respectively.

During 2024, the Laboratory entered into a 20 year operating lease for warehouse space at 327 New South Road, Hicksville, New York. The right-of-use ("ROU") asset and lease liability were recognized at the lease commencement date based on the present value of the lease payments over the lease term. A risk adjusted rate of 4.76% was used to determine the present value of the lease payments, which are recognized on a straight-line basis over the lease term. The operating lease cost is approximately $185,600 for the year ended December 31, 2024.

During 2024, the Laboratory entered into a three year finance lease for scientific equipment. The ROU asset and lease liability were recognized at the lease commencement date based on the present value of the lease payments over the lease term. A risk adjusted rate of 4.09% was used to determine the present value of the lease payments, which are recognized on a straight-line basis over the lease term. The finance lease interest is approximately $14,000 for the year ended December 31, 2024. The related lease liability of approximately $296,500, respectively, is included in accounts payable and accrued expenses at December 31, 2024. The lease includes a purchase option allowing the Laboratory to purchase the equipment at the conclusion of the lease term for a predetermined amount of $1.

The following table reconciles the undiscounted lease payments to the lease liabilities recorded in the accompanying consolidated balance sheets at December 31, 2024:

Year Ending December 31,	Finance Leases	Operating Leases
2025	$ 105,190	$ 288,919
2026	105,190	296,964
2027	105,190	305,028
2028	-	313,416
2029	-	322,035
Thereafter	-	5,947,158
Total minimum lease payments	315,570	7,473,520
Less: amount representing interest	18,977	2,848,955
Net minimum lease payments	$ 296,593	$ 4,624,565

The Laboratory is self-insured for employee medical and prescription benefits beginning January 1, 2008. Under the provisions of this plan, an insurance carrier provided claims processing and administration functions, as well as stop-loss cover age over a stipulated level of claims for the 12-month period ended December 31, 2024. The expense for the program was approximately $16,287,000 and $14,855,000 for the years ended December 31, 2024 and 2023, respectively. The Laboratory accrued approximately $1,600,000 and $1,300,000 for liabilities relating to claims incurred but not reported which are included in accounts payable and accrued expenses for the years ended December 31, 2024 and 2023, respectively.

The Laboratory is currently, and has in the past been, a party to routine litigation incidental to its business. The impact of the final resolution of these matters on the Laboratory's change in net assets or liquidity in a particular reporting period is not known. Management is of the opinion, however, that the ultimate outcome of such matters will not have a materially adverse effect upon the Laboratory's financial condition or liquidity.

NOTE 17 - SUBSEQUENT EVENTS

The Laboratory evaluated events subsequent to December 31, 2024 through May 1, 2025, the date on which the consolidated financial statements were issued for inclusion or disclosure in the consolidated financial statements and noted there were no subsequent events to disclose.

UNIFORM GUIDANCE SUPPLEMENTARY INFORMATION

Cold Spring Harbor Laboratory

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

Year Ended December 31, 2024

Federal Grantor/Pass-through Grantor Cluster or Grant Number	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Research and Development Cluster:				
Research:				
National Science Foundation:				
Direct Awards:				
DUE-2301207	47.076	DIRECT	$ 46,718	$ 213,420
DRL 2321759	47.076	DIRECT	-	654,103
DBI 2421267	47.074	DIRECT	-	44,290
DUE-1821657	47.076	DIRECT	64,612	379,042
IOS 1758800	47.074	DIRECT	162,490	162,490
DBI-2026342	47.074	DIRECT	-	349,693
IOS-2129189	47.074	DIRECT	410,842	1,326,715
IOS-2122358	47.074	DIRECT	-	14,677
MCB-2217560	47.074	DIRECT	-	250,544
IOS-2131631	47.074	DIRECT	-	273,944
IOS-2216612	47.074	DIRECT	662,860	1,045,995
IOS-2224874	47.074	DIRECT	-	294,375
IOS-2328611	47.074	DIRECT	92,314	325,735
Total Direct Awards			1,439,836	5,335,023
Pass-Through Awards:				
NEW YORK UNIVERSITY	47.074	IOS-1934388	-	289,902
Total Pass-Through Awards			-	289,902
Total National Science Foundation			1,439,836	5,624,925
National Institutes of Health:				
Direct Awards:				
2R01GM042699-32	93.859	DIRECT	-	899,621
5R01GM045436-30	93.859	DIRECT	-	1,114,454
2R01CA053840-32	93.396	DIRECT	-	559,479
5R01DK124907-24	93.847	DIRECT	-	560
2P30CA045508-35	93.397	DIRECT	-	4,524,228
2P01CA013106-51	93.396	DIRECT	-	2,735,599
1R01CA290004-01	93.396	DIRECT	-	391,807
1U01CA289357-01	93.393	DIRECT	-	237,402
1F32HG013265-01A1	93.172	DIRECT	-	64,841
1R37CA286477-01A	93.396	DIRECT	-	171,017
1R01CA286780-01A1	93.393	DIRECT	-	162,439
1R01MH136990-01	93.242	DIRECT	-	286,243
1R01CA286651-01	93.396	DIRECT	-	253,384
1R01GM155806-01	93.859	DIRECT	-	184,205
1R01HG012944-01A1	93.172	DIRECT	-	80,809
5P30CA045508-37	93.397	DIRECT	-	474,268
1R25DK132965-02	93.847	DIRECT	-	170,397
1R25GM137355-05	93.859	DIRECT	31,281	214,337
2R01MH085926-12	93.242	DIRECT	-	641,387
5R01CA174793-10	93.396	DIRECT	-	54,072
5R01MH101214-09	93.242	DIRECT	129,869	746,960
2R01MH108924-07	93.242	DIRECT	61,127	674,643
2R01GM117406	93.859	DIRECT	-	427,452
5R50CA211506-08	93.393	DIRECT	-	252,569
5R01MH113005-05	93.242	DIRECT	-	199,710
2R35GM125003-06	93.859	DIRECT	-	177,396
2R01MH113628-06	93.242	DIRECT	-	716,207
5U01CA224013-05	93.396	DIRECT	1,310	76,098
5R01DC017876-05	93.310	DIRECT	-	35,153
1R01MH119819-05	93.242	DIRECT	-	485,558
2R01NS111745-06	93.853	DIRECT	-	537,662
5R01NS111673-05	93.853	DIRECT	-	759,917
5R01MH119250-05	93.242	DIRECT	-	142,822
2R01CA229699-06	93.396	DIRECT	-	324,621
1RF1NS113632-01	93.853	DIRECT	-	365,966
5U01CA242919-05	93.395	DIRECT	-	213,227
5R35GM131833-05	93.859	DIRECT	-	444,949
5R35GM133613-05	93.859	DIRECT	-	562,537
5R35GM133777-05	93.859	DIRECT	-	331,314
2R50CA243890-06	93.396	DIRECT	-	150,807
5R01DA050374-04	93.279	DIRECT	-	298,358
5R01CA237413-04	93.396	DIRECT	19,969	19,969
5R01CA248158-04	93.396	DIRECT	-	300,543
5R01NS116897-04	93.853	DIRECT	-	551,941
1RF1MH125317-01	93.242	DIRECT	-	90
1RF1MH123403-01	93.242	DIRECT	449,204	449,204
5R01GM138669-04	93.859	DIRECT	-	482,939
5R01AG069727-04	93.866	DIRECT	-	250,085
1R01CA249002-03	93.396	DIRECT	-	628,272

The accompanying notes to the schedule of expenditures of federal awards should be read in conjunction with this schedule.

Cold Spring Harbor Laboratory

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS - CONTINUED

Year Ended December 31, 2024

Federal Grantor/Pass-through Grantor Cluster or Grant Number	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
1RF1MH128875-03	93.242	DIRECT	$ 663,097	$ 1,443,355
5R01AI167862-03	93.855	DIRECT	-	850,112
1OT2CA278690-01	93.393	DIRECT	-	608,997
1R01HG011787-02	93.396	DIRECT	-	1,070,186
1U24NS126938	93.853	DIRECT	-	910,353
1R35GM144206	93.859	DIRECT	-	403,309
1R01CA275128	93.396	DIRECT	-	623,706
1DP2MH132943-01	93.242	DIRECT	-	543,390
5R01HG012131-02	93.172	DIRECT	-	374,462
1DP5OD033055-03	93.310	DIRECT	-	536,661
5R01DC020842-02	93.173	DIRECT	-	619,130
1R37CA276938-01	93.396	DIRECT	-	490,336
1R01GM149957-01	93.859	DIRECT	-	454,045
1R01NS131486-01	93.853	DIRECT	-	675,036
2R35GM127070-06	93.859	DIRECT	-	604,218
1RF1NS132046-01	93.853	DIRECT	20,452	628,557
1R01CA281106-01A1	93.396	DIRECT	266,699	641,694
1R01GM149921-01	93.859	DIRECT	-	453,710
1R01CA284630-01	93.393	DIRECT	-	502,594
1R01AG082800-01	93.866	DIRECT	-	653,233
Total Direct Awards			1,643,008	36,914,602
Pass-Through Awards:				
UNIVERSITY OF NEBRASKA MDC	93.394	2U01CA210240-08	-	99,514
NEW YORK UNIVERSITY	93.853	5U19NS112953-05	-	445,859
UNIVERSITY OF MINNESOTA	93.393	5R01CA236948-05	-	26,034
SUNY-STONY BROOK	93.395	5R01CA237154-04	-	234,630
SALK INSTITUTE FOR BIOLOGICAL STUDIES	93.866	1RF1AG064049-01	-	132,476
DUKE UNIVERSITY	93.242	1RF1MH125921-03	-	14,765
BAYLOR COLLEGE OF MEDICINE	93.242	1RF1-MH126883-01A1	-	350,780
SUNY-STONY BROOK	93.398	1F30CA281082-01	-	5,339
CORNELL UNIVERSITY	93.396	1R01CA272466	-	79,883
MASSACHUSETTS INSTITUTE OF TECHNOLOGY	93.853	1UM1NS132173-02	-	210,396
THOMAS JEFFERSON UNIVERSITY	93.242	080-19250-S51201	-	22,715
SUNY-STONY BROOK	93.398	1F31CA290937-01	-	1,938
UNIVERSITY OF CALIFORNIA DAVIS	93.242	1R01MH135937-01	-	159,285
MASSACHUSETTS INSTITUTE OF TECHNOLOGY	93.242	1UG3MH126869-03	-	462,592
SUNY-STONY BROOK	93.866	1RO1AG076937-01	-	17,215
THE BROAD INSTITUTE	93.242	1U24MH130968-01	-	9,330
SUNY-STONY BROOK	93.398	1F30CA281196-01	-	3,838
BAYLOR COLLEGE OF MEDICINE	93.853	1U01NS132353-01	-	115,598
UNIVERSITY OF MINNESOTA	93.853	1UM1NS132207-01	-	118,477
SUNY-STONY BROOK	93.242	1R01MH134776-01A1	-	19,130
CARNEGIE MELLON UNIVERSITY	93.867	R01EY037194	-	70,801
MASSACHUSETTS INSTITUTE OF TECHNOLOGY	93.853	1UM1NS132173-01	-	708,478
COLUMBIA UNIVERSITY	93.853	1U19NS123716-03	-	802,189
SUNY-BINGHAMTON UNIVERSITY	93.853	1R01NS122226-02A2	-	129
Total Pass-Through Awards			-	4,111,391
Total National Institutes of Health			1,643,008	41,025,993
Department of Agriculture:				
Direct Awards:				
59-8062-9-002	10.001	DIRECT	-	14
2020-67013-30909	10.310	DIRECT	-	204,111
59-8062-2-010	10.001	DIRECT	-	2,077,427
Total Department of Agriculture			-	2,281,552
Department of Energy:				
Direct Awards:				
DE-SC0018244	81.049	DIRECT	-	29,317
DE-SC0023536	81.049	DIRECT	-	132,681
Total Department of Energy			-	161,998
United States Army:				
Direct Awards:				
W81XWH-20-1-0753	12.420	DIRECT	-	36,118
W81XWH-20-1-0754	12.420	DIRECT	-	415,417
W81XWH2110071	12.420	DIRECT	-	28,903
W81XWH-22-10-358	12.420	DIRECT	-	130,360
W81XWH2210045	12.420	DIRECT	-	537

The accompanying notes to the schedule of expenditures of federal awards should be read in conjunction with this schedule.

Cold Spring Harbor Laboratory

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS - CONTINUED

Year Ended December 31, 2024

Federal Grantor/Pass-through Grantor Cluster or Grant Number	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
W81XWH2210871	12.420	DIRECT	$ 24,998	$ 452,792
W81XWH2210380	12.420	DIRECT	-	304,134
HT94252410091	12.420	DIRECT	3,511	148,306
HT94252410631	12.420	DIRECT	-	80,981
Total United States Army			28,509	1,597,548
Total Research			3,111,353	50,692,016
Non-Research:				
DNA Literacy Program:				
National Science Foundation:				
Pass-Through Awards:				
UNIVERSITY OF ARIZONA	47.074	DBI-1743442	-	655
AUSTIN COMMUNITY COLLEGE	47.076	DUE-1901984	-	200,805
UNIVERSITY OF MINNESOTA	47.076	2228971	-	180,656
Total National Science Foundation			-	382,116
U.S. Department of Education:				
Pass-Through Awards:				
LOS ANGELES PIERCE COLLEGE	84.116	4500293584	-	49,293
Total U.S. Department of Education			-	49,293
Federal Pass-Through:				
Pass-Through Awards:				
AUSTIN COMMUNITY COLLEGE	47.076	DUE- 2349809	-	23,894
Total U.S. Department of Education			-	23,894
Total DNA Literacy Program			-	455,303
National Institutes of Health:				
Direct Awards:				
2R13HG003676-20	93.172	DIRECT	-	71,178
1R13HG013261-01	93.172	DIRECT	-	5,412
1R13CA287957-01	93.398	DIRECT	-	5,000
1R13AI183663-01	93.855	DIRECT	-	12,000
1R13NS137697-01	93.853	DIRECT	-	29,000
1R13NS137721-01	93.853	DIRECT	-	31,265
1R13AG087518-01	93.866	DIRECT	-	33,290
1R25NS137380-01	93.853	DIRECT	-	168,109
1R13AG089879-01	93.866	DIRECT	-	30,945
R13AG089747-01	93.866	DIRECT	-	36,525
1R13CA290707-01	93.398	DIRECT	-	19,859
1R13AI186427-01	93.855	DIRECT	-	6,500
5R13AI129217-08	93.855	DIRECT	-	38,855
5R13HG010975-05	93.172	DIRECT	-	38,957
5R13HD102100-05	93.865	DIRECT	-	10,000
Total National Institutes of Health			-	536,895
Total Meetings			-	536,895
In-House Training and Fellowships:				
National Science Foundation:				
Direct Awards:				
DGE-1938105	47.076	DIRECT	-	154,970
Total National Science Foundation			-	154,970
National Institutes of Health:				
Direct Awards:				
1K99GM149939-01	93.859	DIRECT	-	58,527
1K99CA273523-01A1	93.398	DIRECT	-	76,265
1K22CA279501-01	93.398	DIRECT	-	203,926
1F31CA278591-01	93.398	DIRECT	-	53,044
1F31CA281246-01	93.398	DIRECT	-	48,524
Total National Institutes of Health			-	440,286
Total In-House Training and Fellowships			-	595,256

The accompanying notes to the schedule of expenditures of federal awards should be read in conjunction with this schedule.

Cold Spring Harbor Laboratory

SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS - CONTINUED

Year Ended December 31, 2024

Federal Grantor/Pass-through Grantor Cluster or Grant Number	Federal Assistance Listing Number	Pass-Through Entity Identifying Number	Passed Through to Subrecipients	Total Federal Expenditures
Outside Courses and Training:				
National Science Foundation:				
Direct Awards:				
DUE-2216349	47.076	DIRECT	$ -	$ 63,774
IOS-1949855	47.074	DIRECT	-	198,261
MCB 2207222	47.074	DIRECT	-	221,562
MCB-2316459	47.074	DIRECT	-	406,859
Total National Science Foundation			-	890,456
National Institutes of Health:				
Direct Awards:				
5R25CA078139-24	93.398	DIRECT	-	138,545
5R25HG007825-09	93.172	DIRECT	-	95,411
5R25HD030269-30	93.865	DIRECT	-	189,433
2R25CA009481-39	93.398	DIRECT	-	322,841
2R13DA019791-14	93.279	DIRECT	-	40,000
1R25AI182956-01	93.855	DIRECT	-	124,614
2R25HG006424-12	93.172	DIRECT	-	85,964
2R25HD072999-10	93.865	DIRECT	-	102,879
1R25HG011448-03	93.172	DIRECT	-	86,633
5R25HG007819-10	93.172	DIRECT	-	73,931
5R25MH107360-10	93.242	DIRECT	-	188,976
5R25MH122360-04	93.242	DIRECT	-	171,969
1R25HD111361-01	93.865	DIRECT	-	161,601
1R25GM144246-02	93.859	DIRECT	-	235,936
Total National Institutes of Health			-	2,018,733
Total Outside Courses and Training			-	2,909,189
Equipment:				
National Institutes of Health:				
Direct Awards:				
1CE1HS52087-01-00	93.493	DIRECT	-	1,997,500
Total National Institutes of Health			-	1,997,500
Total Equipment			-	1,997,500
Total Non-Research			-	6,494,143
Total Research and Development Cluster			3,111,353	57,186,159
Total Expenditures of Federal Awards			$ 3,111,353	$ 57,186,159

The accompanying notes to the schedule of expenditures of federal awards should be read in conjunction with this schedule.

Cold Spring Harbor Laboratory

NOTES TO SCHEDULE OF EXPENDITURES OF FEDERAL AWARDS

December 31, 2024

NOTE 1 - BASIS OF PRESENTATION

The accompanying schedule of expenditures of federal awards (the "Schedule") includes the federal award activity of Cold Spring Harbor Laboratory (the "Laboratory") under programs of the federal government for the year ended December 31, 2024 and is prepared on the accrual basis of accounting. The information in this Schedule is presented in accordance with the requirements of Title 2 U.S. *Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Because the Schedule presents only a selected portion of the operations of the Laboratory, it is not intended to and does not present the financial position, change in net assets, or cash flows of the Laboratory.

All of the Laboratory's grants are categorized within the research and development cluster. The subcategories delineated in the accompanying schedule of expenditures of federal awards are utilized by the Laboratory for its internal reporting.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Expenditures reported on the Schedule are reported on the accrual basis of accounting. Such expenditures are recognized following the cost principles contained in the Uniform Guidance, wherein certain types of expenditures are not allowable or are limited as to reimbursement. The Laboratory has not elected to use the 10% *de minimis* indirect cost rate as allowed under the Uniform Guidance as indirect cost allowances recovered under government grants are based on an approved indirect cost rate negotiated with the cognizant government granting agency.

GRANT THORNTON LLP
445 Broadhollow Road, Suite 300
Melville, NY 11747

D +1 631 249 6001
F +1 631 249 6144

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS ON INTERNAL CONTROL OVER FINANCIAL REPORTING AND ON COMPLIANCE AND OTHER MATTERS REQUIRED BY *GOVERNMENT AUDITING STANDARDS*

Board of Trustees
Cold Spring Harbor Laboratory

We have audited, in accordance with auditing standards generally accepted in the United States of America and the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*), the consolidated financial statements of Cold Spring Harbor Laboratory (the "Laboratory"), which comprise the consolidated balance sheet as of December 31, 2024, and the related consolidated statements of activities and cash flows for the year then ended, and the related notes to the consolidated financial statements, and have issued our report thereon dated May 1, 2025.

Report on internal control over financial reporting
In planning and performing our audit of the consolidated financial statements, we considered the Laboratory's internal control over financial reporting ("internal control") as a basis for designing audit procedures that are appropriate in the circumstances for the purpose of expressing our opinion on the financial statements, but not for the purpose of expressing an opinion on the effectiveness of the Laboratory's internal control. Accordingly, we do not express an opinion on the effectiveness of the Laboratory's internal control.

A deficiency in internal control exists when the design or operation of a control does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, misstatements on a timely basis. A material weakness is a deficiency, or a combination of deficiencies, in internal control, such that there is a reasonable possibility that a material misstatement of the Laboratory's consolidated financial statements will not be prevented, or detected and corrected, on a timely basis. A significant deficiency is a deficiency, or a combination of deficiencies, in internal control that is less severe than a material weakness, yet important enough to merit attention by those charged with governance.

Our consideration of internal control was for the limited purpose described in the first paragraph of this section and was not designed to identify all deficiencies in internal control that might be material weaknesses or significant deficiencies. Given these limitations, during our audit we did not identify any deficiencies in internal control that we consider to be material weaknesses. However, material weaknesses or significant deficiencies may exist that were not identified.

Grant Thornton LLP is a U.S. member firm of Grant Thornton International Ltd (GTIL). GTIL and each of its member firms are separate legal entities and are not a worldwide partnership.

Report on compliance and other matters
As part of obtaining reasonable assurance about whether the Laboratory's consolidated financial statements are free from material misstatement, we performed tests of its compliance with certain provisions of laws, regulations, contracts, and grant agreements, noncompliance with which could have a direct and material effect on the consolidated financial statements.

However, providing an opinion on compliance with those provisions was not an objective of our audit, and accordingly, we do not express such an opinion. The results of our tests disclosed no instances of noncompliance or other matters that are required to be reported under *Government Auditing Standards*.

Purpose of this report
The purpose of this report is solely to describe the scope of our testing of internal control and compliance and the results of that testing, and not to provide an opinion on the effectiveness of the Laboratory's internal control or on compliance. This report is an integral part of an audit performed in accordance with *Government Auditing Standards* in considering the Laboratory's internal control and compliance. Accordingly, this communication is not suitable for any other purpose.

Grant Thornton LLP

Melville, New York
May 1, 2025

GRANT THORNTON LLP
445 Broadhollow Road, Suite 300
Melville, NY 11747

D +1 631 249 6001
F +1 631 249 6144

REPORT OF INDEPENDENT CERTIFIED PUBLIC ACCOUNTANTS ON COMPLIANCE FOR EACH MAJOR FEDERAL PROGRAM AND ON INTERNAL CONTROL OVER COMPLIANCE REQUIRED BY THE UNIFORM GUIDANCE

Board of Trustees
Cold Spring Harbor Laboratory

Report on compliance for the major federal program

Opinion on each major federal program

We have audited the compliance of Cold Spring Harbor Laboratory (the "Laboratory") with the types of compliance requirements identified as subject to audit in the *OMB Compliance Supplement* that could have a direct and material effect on the Laboratory's major federal program for the year ended December 31, 2024. The Laboratory's major federal program is identified in the summary of auditor's results section of the accompanying schedule of findings and questioned costs.

In our opinion, the Laboratory complied, in all material respects, with the compliance requirements referred to above that could have a direct and material effect on its major federal program for the year ended December 31, 2024.

Basis for opinion on the major federal program

We conducted our audit of compliance in accordance with auditing standards generally accepted in the United States of America (US GAAS); the standards applicable to financial audits contained in *Government Auditing Standards* issued by the Comptroller General of the United States (*Government Auditing Standards*); and the audit requirements of Title 2 *U.S. Code of Federal Regulations* Part 200, *Uniform Administrative Requirements, Cost Principles, and Audit Requirements for Federal Awards* (Uniform Guidance). Our responsibilities under those standards and the Uniform Guidance are further described in the Auditor's Responsibilities for the Audit of Compliance section of our report.

We are required to be independent of the Laboratory and to meet our other ethical responsibilities in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion on compliance for the major federal program. Our audit does not provide a legal determination of the Laboratory's compliance with the compliance requirements referred to above.

Responsibilities of management for compliance

Management is responsible for compliance with the requirements referred to above and for the design, implementation, and maintenance of effective internal control over compliance with the requirements of laws, statutes, regulations, rules and provisions of contracts or grant agreements applicable to the Laboratory's federal program.

Grant Thornton LLP is a U.S. member firm of Grant Thornton International Ltd (GTIL). GTIL and each of its member firms are separate legal entities and are not a worldwide partnership.

Auditor's responsibilities for the audit of compliance
Our objectives are to obtain reasonable assurance about whether material noncompliance with the compliance requirements referred to above occurred, whether due to fraud or error, and express an opinion on the Laboratory's compliance based on our audit. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance will always detect material noncompliance when it exists. The risk of not detecting material noncompliance resulting from fraud is higher than for that resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Noncompliance with the compliance requirements referred to above is considered material if there is a substantial likelihood that, individually or in the aggregate, it would influence the judgment made by a reasonable user of the report on compliance about the Laboratory's compliance with the requirements of the major federal program as a whole.

In performing an audit in accordance with US GAAS, *Government Auditing Standards*, and the Uniform Guidance, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material noncompliance, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the Laboratory's compliance with the compliance requirements referred to above and performing such other procedures as we considered necessary in the circumstances.
- Obtain an understanding of the Laboratory's internal control over compliance relevant to the audit in order to design audit procedures that are appropriate in the circumstances and to test and report on internal control over compliance in accordance with the Uniform Guidance, but not for the purpose of expressing an opinion on the effectiveness of the Laboratory's internal control over compliance. Accordingly, no such opinion is expressed.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, and any significant deficiencies and material weaknesses in internal control over compliance that we identified during the audit.

Report on internal control over compliance
A deficiency in internal control over compliance exists when the design or operation of a control over compliance does not allow management or employees, in the normal course of performing their assigned functions, to prevent, or detect and correct, noncompliance with a type of compliance requirement of a federal program on a timely basis. A material weakness in internal control over compliance is a deficiency, or a combination of deficiencies, in internal control over compliance, such that there is a reasonable possibility that material noncompliance with a type of compliance requirement of a federal program will not be prevented, or detected and corrected, on a timely basis. A significant deficiency in internal control over compliance is a deficiency, or a combination of

deficiencies, in internal control over compliance with a type of compliance requirement of a federal program that is less severe than a material weakness in internal control over compliance, yet important enough to merit attention by those charged with governance.

Our consideration of internal control over compliance was for the limited purpose described in the Auditor's Responsibilities for the Audit of Compliance section above and was not designed to identify all deficiencies in internal control over compliance that might be material weaknesses or significant deficiencies in internal control over compliance. Given these limitations, during our audit we did not identify any deficiencies in internal control over compliance that we consider to be material weaknesses or significant deficiencies. However, material weaknesses or significant deficiencies in internal control over compliance may exist that were not identified.

Our audit was not designed for the purpose of expressing an opinion on the effectiveness of internal control over compliance. Accordingly, no such opinion is expressed.

The purpose of this Report on Internal Control Over Compliance is solely to describe the scope of our testing of internal control over compliance and the results of that testing based on the requirements of the Uniform Guidance. Accordingly, this report is not suitable for any other purpose.

Grant Thornton LLP

Melville, New York
June 4, 2025

Cold Spring Harbor Laboratory

SCHEDULE OF FINDINGS AND QUESTIONED COSTS

December 31, 2024

SECTION I - SUMMARY OF AUDITOR'S RESULTS

Consolidated Financial Statements

Type of auditors' report issued:			Unmodified	
Internal control over financial reporting:				
Material weakness(es) identified?	____	yes	X	none reported
Significant deficiency(ies) identified?	____	yes	X	none reported
Noncompliance material to financial statements noted?	____	yes	X	none reported

Federal Awards

Internal control over the major program:				
Material weakness(es) identified?	____	yes	X	none reported
Significant deficiency(ies) identified?	____	yes	X	none reported
Type of auditors' report issued on compliance for the major program:			Unmodified	
Any audit findings disclosed that are required to be reported in accordance with Subpart F, Section 200.516(a) of the Uniform Guidance?	____	yes	X	none reported

Identification of the major program:

Federal Grantor/Program or Cluster Title	Federal Assistance Listing Number
Research and development cluster	Various

Dollar threshold used to distinguish between type A and type B programs:			$1,715,585	
Auditee qualified as low-risk auditee?	X	yes	____	no

SECTION II - FINANCIAL STATEMENT FINDINGS

None noted.

SECTION III - FINDINGS AND QUESTIONED COSTS FOR FEDERAL AWARDS

None noted.